157 related articles for article (PubMed ID: 30076278)
1. Non-Small Cell Lung Cancer in Countries of Central and Southeastern Europe: Diagnostic Procedures and Treatment Reimbursement Surveyed by the Central European Cooperative Oncology Group.
Ryska A; Buiga R; Fakirova A; Kern I; Olszewski W; Plank L; Seiwerth S; Toth E; Zivka E; Thallinger C; Zielinski C; Brcic L
Oncologist; 2018 Dec; 23(12):e152-e158. PubMed ID: 30076278
[TBL] [Abstract][Full Text] [Related]
2. Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis.
Cufer T; Ciuleanu TE; Berzinec P; Galffy G; Jakopovic M; Jassem J; Jovanovic D; Mihaylova Z; Ostoros G; Thallinger C; Zemanova M; Zielinski C
Oncologist; 2020 Mar; 25(3):e598-e601. PubMed ID: 32162818
[TBL] [Abstract][Full Text] [Related]
3. Treatment patterns and real-world evidence for stage III non-small cell lung cancer in Central and Eastern Europe.
Zemanova M; Jakopovic M; Stanic K; Łazar-Poniatowska M; Vrankar M; Rusu P; Ciuleanu T; Radosavljevic D; Bogos K; Nawrocki S
Radiol Oncol; 2020 Oct; 54(4):447-454. PubMed ID: 33048837
[TBL] [Abstract][Full Text] [Related]
4. NSCLC molecular testing in Central and Eastern European countries.
Ryska A; Berzinec P; Brcic L; Cufer T; Dziadziuszko R; Gottfried M; Kovalszky I; Olszewski W; Oz B; Plank L; Timar J
BMC Cancer; 2018 Mar; 18(1):269. PubMed ID: 29523116
[TBL] [Abstract][Full Text] [Related]
5. Lung cancer biomarker testing: perspective from Europe.
Thunnissen E; Weynand B; Udovicic-Gagula D; Brcic L; Szolkowska M; Hofman P; Smojver-Ježek S; Anttila S; Calabrese F; Kern I; Skov B; Perner S; Dale VG; Eri Z; Haragan A; Leonte D; Carvallo L; Prince SS; Nicholson S; Sansano I; Ryska A
Transl Lung Cancer Res; 2020 Jun; 9(3):887-897. PubMed ID: 32676354
[TBL] [Abstract][Full Text] [Related]
6. Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): a European survey conducted by the European Society for Medical Oncology (ESMO) young oncologists committee.
Califano R; Karamouzis MV; Banerjee S; de Azambuja E; Guarneri V; Hutka M; Jordan K; Kamposioras K; Martinelli E; Corral J; Postel-Vinay S; Preusser M; Porcu L; Torri V
Lung Cancer; 2014 Jul; 85(1):74-80. PubMed ID: 24746176
[TBL] [Abstract][Full Text] [Related]
7. Second-Line Treatment Selection in Patients With Non-Small-Cell Lung Cancer of Adenocarcinoma Histology: Findings From a European Survey of Treating Physicians.
Girard N; Corral J; Cortinovis D; Heigener DF
Clin Lung Cancer; 2017 Mar; 18(2):e89-e97. PubMed ID: 27865625
[TBL] [Abstract][Full Text] [Related]
8. Clinical management patterns and treatment outcomes in patients with non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study.
Carrato A; Vergnenègre A; Thomas M; McBride K; Medina J; Cruciani G
Curr Med Res Opin; 2014 Mar; 30(3):447-61. PubMed ID: 24168104
[TBL] [Abstract][Full Text] [Related]
9. A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506).
Zhou Q; Song Y; Zhang X; Chen GY; Zhong DS; Yu Z; Yu P; Zhang YP; Chen JH; Hu Y; Feng GS; Song X; Shi Q; Yang LL; Zhang PH; Wu YL
BMC Cancer; 2017 Jul; 17(1):462. PubMed ID: 28673332
[TBL] [Abstract][Full Text] [Related]
10. Oral vinorelbine plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of advanced non-squamous non-small-cell lung cancer: cost minimization analysis in 12 European countries.
Grossi F; Bennouna J; Havel L; Hochmair M; Almodovar T
Curr Med Res Opin; 2016 Sep; 32(9):1577-84. PubMed ID: 27223813
[TBL] [Abstract][Full Text] [Related]
11. Approach to the non-operative management of patients with stage II non-small cell lung cancer (NSCLC): A survey of Canadian medical and radiation oncologists.
Dudani S; Leighl NB; Ho C; Pantarotto JR; Zhu X; Zhang T; Wheatley-Price P
Lung Cancer; 2016 Apr; 94():74-80. PubMed ID: 26973210
[TBL] [Abstract][Full Text] [Related]
12. Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage.
Wood R; Taylor-Stokes G
BMC Cancer; 2019 Mar; 19(1):214. PubMed ID: 30849964
[TBL] [Abstract][Full Text] [Related]
13. Expenditures on Oncology Drugs and Cancer Mortality-to-Incidence Ratio in Central and Eastern Europe.
Vrdoljak E; Bodoky G; Jassem J; Popescu R; Pirker R; Čufer T; Bešlija S; Eniu A; Todorović V; Kopečková K; Kurteva G; Tomašević Z; Sallaku A; Smichkoska S; Bajić Ž; Sikic B
Oncologist; 2019 Jan; 24(1):e30-e37. PubMed ID: 30181313
[TBL] [Abstract][Full Text] [Related]
14. Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement.
Vrdoljak E; Bodoky G; Jassem J; Popescu RA; Mardiak J; Pirker R; Čufer T; Bešlija S; Eniu A; Todorović V; Kubáčková K; Kurteva G; Tomašević Z; Sallaku A; Smichkoska S; Bajić Ž; Šikić BI
Oncologist; 2016 Oct; 21(10):1183-1190. PubMed ID: 27401890
[TBL] [Abstract][Full Text] [Related]
15. Non-small cell lung cancer, version 1.2015.
Ettinger DS; Wood DE; Akerley W; Bazhenova LA; Borghaei H; Camidge DR; Cheney RT; Chirieac LR; D'Amico TA; Demmy TL; Dilling TJ; Govindan R; Grannis FW; Horn L; Jahan TM; Komaki R; Kris MG; Krug LM; Lackner RP; Lanuti M; Lilenbaum R; Lin J; Loo BW; Martins R; Otterson GA; Patel JD; Pisters KM; Reckamp K; Riely GJ; Rohren E; Schild S; Shapiro TA; Swanson SJ; Tauer K; Yang SC; Gregory K; Hughes M
J Natl Compr Canc Netw; 2014 Dec; 12(12):1738-61. PubMed ID: 25505215
[TBL] [Abstract][Full Text] [Related]
16. Treatment decision-making for advanced non-small cell lung cancer and differences among European countries: 1st AIOT-ETOP meeting.
Gridelli C; Stahel R; Besse B; Ciardiello F; Felip E; Gasparini S; Graziano P; Rossi A; de Marinis F
Lung Cancer; 2011 Dec; 74(3):544-8. PubMed ID: 21958448
[TBL] [Abstract][Full Text] [Related]
17. Treatment cost of non-small cell lung cancer in three European countries: comparisons across France, Germany, and England using administrative databases.
McGuire A; Martin M; Lenz C; Sollano JA
J Med Econ; 2015; 18(7):525-32. PubMed ID: 25802950
[TBL] [Abstract][Full Text] [Related]
18. [MANAGEMENT OF NON-SMALL CELL LUNG CANCER].
Sibille A; Paulus A; Martin M; Bourhaba M; Barthélemy N; Radermecker M; Corhay JL; Louis R; Duysinx B
Rev Med Liege; 2015 Sep; 70(9):432-41. PubMed ID: 26638443
[TBL] [Abstract][Full Text] [Related]
19. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Vansteenkiste J; De Ruysscher D; Eberhardt WE; Lim E; Senan S; Felip E; Peters S;
Ann Oncol; 2013 Oct; 24 Suppl 6():vi89-98. PubMed ID: 23860613
[No Abstract] [Full Text] [Related]
20. Utility values associated with advanced or metastatic non-small cell lung cancer: data needs for economic modeling.
Brown J; Cook K; Adamski K; Lau J; Bargo D; Breen S; Chawla A
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):153-164. PubMed ID: 28335636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
